As of August 2026, according to Iradimed's latest financial report, the company's current EPS (TTM) is $1.82. Iradimed's EPS for 2025 came in at $1.77, marking an increase from $1.52 in 2024. Iradimed's earnings per share for the quarterly report ending on Jun 30, 2026 was $0.41.
The annual EPS in 2025 was $1.77, an increase of 16.4% from $1.52 in 2024. The quarterly EPS for the period ending Jun 30, 2026, was $0.41, marking a 8.9% decrease from the same quarter last year. IRMD's TTM EPS stands at $1.82 as of June 2026. Iradimed's EPS for 2024 stood at $1.52, a 11.8% increase from 2023.
Iradimed has recorded a decrease in EPS of 8.9% over the last 12 months (YoY, quarterly). For the last three years, IRMD recorded an average annual EPS growth rate of 20.2%. Iradimed had an average annual EPS growth rate of 71.3% over the last 5 years. Across the last decade, IRMD had an average annual EPS growth of 10%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| DXCM Dexcom Inc | 34.65 | 46.6% | 34.5% | 7.9% |
| IRMD Iradimed Corp | 47.77 | 16.4% | 20.2% | 71.3% |
| EW Edwards Lifesciences Corp | 52.64 | -73.6% | -9.2% | 6.9% |
| COO Cooper Companies Inc | 64.01 | -4.6% | -1.2% | 9.2% |
All data is based on quarterly TTM periods, unless otherwise specified.